argenx NV ADR

argenx NV ADR

Yahoo Finance • 5 days ago

argenx to Host Autoimmune Myositis R&D Webinar

June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled “R&D Sp... Full story

Yahoo Finance • 22 days ago

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week

European equities traded in the US as American depositary receipts were tracking lower late Friday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 23 days ago

How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story

In recent days, Halozyme Therapeutics’ partner argenx reported positive new data for a therapy using Halozyme’s ENHANZE® drug delivery technology, while an analyst reaffirmed a positive rating on the company. This combination of external c... Full story

Yahoo Finance • 24 days ago

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were declining late Wednesday mor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 25 days ago

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren’s disease indicate maintenance of response following switch to biweekly dosingCross-indicatio... Full story

Yahoo Finance • last month

argenx to Host Myositis R&D Webinar on June 23, 2026

May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled... Full story

Yahoo Finance • last month

argenx to Present at Upcoming Investor Conferences

May 27, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management... Full story

Yahoo Finance • last month

Can a New Arthritis Drug Make Immunovant the Next Biotech Star?

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • last month

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • last month

Jefferies updates Franchise Picks list, adding AMZN, APP, MCD and more

[Wall Street Bull] DNY59/iStock Unreleased via Getty Images Jefferies refreshed its Franchise Picks list Monday. Its equity team added Amazon (AMZN [https://seekingalpha.com/symbol/AMZN]), AppLovin (APP [https://seekingalpha.com/symbol/A... Full story

Yahoo Finance • last month

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics(NASDAQ:NKTR). The estimated value of the trade was... Full story

Yahoo Finance • last month

Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial

argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Syst... Full story

Yahoo Finance • 2 months ago

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx SE VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients t... Full story

Yahoo Finance • 2 months ago

Zoetis Crashes As Even Slashed Guidance Appears To Be A 'Heavy Lift'

Zoetis stock crashed early Thursday after the pet health company cut its outlook on a sales and earnings miss. Continue Reading... Full story

Yahoo Finance • 2 months ago

argenx SE GAAP EPS of $5.52 beats by $0.31, revenue of $1.3B misses by $10M

* argenx SE press release [https://seekingalpha.com/pr/20504728-argenx-reports-first-quarter-2026-financial-results-and-provides-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q1 GAAP EPS of $5.52 beats by $0.31. * Rev... Full story

Yahoo Finance • 2 months ago

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune... Full story

Yahoo Finance • 2 months ago

Here’s Why Argenx SE (ARGX) Slipped in Q1

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Sha... Full story

Yahoo Finance • 2 months ago

Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion

Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD Cowen maintained its Buy rating and $1,146 price target for Argenx SE (NASDAQ:ARGX), citing a quarterly monitoring poll that indicated first... Full story

Yahoo Finance • 2 months ago

European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were falling sharply late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study results build on VYV... Full story